MECHANISM OF ACTION
DSIP (delta sleep-inducing peptide) is a neuropeptide originally isolated from rabbit thalamus by Schoenenberger & Monnier (1977). It promotes delta-wave sleep through opioid receptor modulation and GABA enhancement, without the addictive liability of pharmacological sleep aids. Additionally shown to modulate the HPA axis - reducing ACTH and cortisol under stress conditions - and exert antioxidant and anti-apoptotic neuroprotective effects in some rodent models. Also used in Russian clinical practice for stress and withdrawal syndromes.
RESEARCH APPLICATIONS
- Sleep quality and delta-wave architecture research
- HPA axis stress response modulation
- Opioid withdrawal and substance dependence models
- Neuroprotection and anti-apoptotic models
- Circadian rhythm and neuroendocrine research
RESEARCH HIGHLIGHTS
Original Delta Sleep Induction
1977First characterised as the active component in cerebral venous blood of sleeping rabbits - intraventricular injection produced reproducible delta sleep pattern in recipient rabbits.
Ref: Monnier et al., Pflügers Arch
HPA Axis Attenuation
1986DSIP administration reduced ACTH and corticosterone response to restraint stress in rodent models, proposing a role in HPA axis buffering.
Ref: Graf & Kastin, Neurosci Biobehav Rev
RESEARCH PROTOCOL NOTES
Chemical Identity
Sequence
Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu
Storage & Stability
Lyophilised: -20°C. Reconstituted: 2–8°C, 14 days. Relatively unstable in solution - use promptly.
Regulatory Status
Used in Russian practice for stress/withdrawal (not formally registered as drug). No FDA/EMA approval. Research compound. Not WADA prohibited.